Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS

Condition(s) targeted: Seasonal Allergic Rhinitis

Intervention: fluticasone propionate, fluticasone furoate (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, MD, Study Director, Affiliation: GlaxoSmithKline

The purpose of this replicate study to FFU105924 is to provide data on subject preference of FFNS as compared with FPNS.

Official title: A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy, Patient Preference and Experience of One-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects With Seasonal Allergic Rhinitis (FFU105927)

Study design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study

Primary outcome: Mean change from baseline in daily rTNSS over the treatment period following treatment with FFNS vs. placebo and FPNS vs. placebo

Secondary outcome:

AM and PM rTNSS Health outcomes endpoints - subject experience with nasal sprays and subject preference for either nasal sprays

Subject preference for either FFNS or FPNS based on the following attributes at the end of the cross-over period: Leaking out of nose/down throat Ease of use Gentleness of mist

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Informed consent Subject has provided an appropriately signed and dated informed

consent. Otherwise healthy outpatient with fall allergy Subject is treatable on an outpatient basis. Age 18 years or age or older at time of Visit 2 Male or eligible female Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test will be required of all females at all visits to determine if the subject is pregnant.

To be eligible for entry into the study, females of childbearing potential must commit to the consistent and correct use of an acceptable method of birth control, as defined by the following:

Abstinence Females of childbearing potential who are not sexually active must commit to complete abstinence from intercourse for two weeks before exposure to the study drug, throughout the clinical trial, and for a period after the trial to account for elimination of the drug (minimum of six days).

Oral contraceptive (either combined estrogen/progestin or progestin only) Injectable progestogen Implants of levonorgestrel Percutaneous contraceptive patches Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year, Male partner who is sterile (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study and is the sole sexual partner for that female subject Double barrier method-condom or occlusive cap (diaphragm or cervical /vault caps) plus spermicide Estrogenic vaginal ring

- Diagnosis of SAR

SAR is defined as follows:

A clinical history (written or verbal) of SAR with seasonal allergy symptoms (nasal symptoms) during each of the last two fall allergy seasons, and A positive skin test (by prick method) to fall allergen prevalent to the geographic area during the conduct of the study, within 12 months prior to Visit 1 or at Visit 1.

A positive skin test is defined as a wheal 3 mm larger than the diluent control for prick testing.

In vitro tests for specific IgE (such as RAST, PRIST) will not be allowed as a diagnosis of SAR.

Subjects who meet the above criteria and who may also have perennial allergic rhinitis or vasomotor rhinitis are eligible for randomization.

- Adequate exposure to seasonal pollen Subject resides within a geographical region

where exposure to fall seasonal allergen is expected to be significant during the entire study period.

Subject does not plan to travel outside this area for more than 48 hours of the study period.

- Ability to comply with study procedures Subject understands and is willing, able and

likely to comply with study procedures and restrictions.

- Literate

Exclusion Criteria:

Recent use (less than 1 year) of using branded (FLONASE) or generic FPNS or use of FFNS (VERAMYST).

Significant concomitant medical conditions, defined as but not limited to:

A historical or current evidence of clinically significant uncontrolled disease of any body system (e. g., tuberculosis, psychological disorders, eczema). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or which would confound the interpretation of the study results if the disease/condition exacerbated during the study.

A severe physical obstruction of the nose (e. g., deviated septum or nasal polyp) or nasal septal perforation that could affect the deposition of intranasal study drug Nasal (eg, nasal septum) injury or surgery in the last 3 months Asthma, with the exception of mild intermittent asthma [National Asthma Education and Prevention Program (NARPP) Guidelines, 2002].

Rhinitis medicamentosa Bacterial or viral infection (e. g., common cold) of the eyes or upper respiratory tract within two weeks of Visit 1 or during the screening period Documented evidence of acute or significant chronic sinusitis, as determined by the individual investigator Current or history of glaucoma and/or cataracts or ocular herpes simplex Physical impairment that would affect subject's ability to participate safely and fully in the study Clinical evidence of a Candida infection of the nose History of psychiatric disease, intellectual deficiency, poor motivation, substance abuse (including drug and alcohol) or other conditions that will limit the validity of informed consent or that would confound the interpretation of the study results History of adrenal insufficiency History of shingles Chickenpox or measles: A subject is not eligible if he/she currently has chickenpox or measles, or has been exposed to chickenpox or measles during the last 3 weeks and is non-immune. If a subject develops chickenpox or measles during the study, he/she will be withdrawn from the study. If a non-immune subject is exposed to chickenpox or measles during the study, his/her continuation in the study will be at the discretion of the investigator, taking into consideration the likelihood of developing active disease.

Use of other corticosteroids, defined as:

Intranasal corticosteroid within four weeks prior to Visit 1. Inhaled, oral, intramuscular, intravenous, ocular, and/or dermatological corticosteroid (with the exception of hydrocortisone cream/ointment, 1% or less) within eight weeks prior to Visit 1.

Use of other allergy medications within the timeframe indicated relative to Visit 1 Intranasal cromolyn within 14 days prior to Visit 1 Short-acting prescription and OTC antihistamines, including antihistamines contained in insomnia and 'nighttime' pain formulations taken for insomnia, within 3 days prior to Visit 1 Long-acting antihistamines within 10 days prior to Visit 1: loratadine, desloratadine, fexofenadine, cetirizine Oral or intranasal decongestants within 3 days prior to Visit 1 Intranasal, oral, or inhaled anticholinergics within 3 days prior to Visit 1 Oral antileukotrienes within 3 days prior to Visit 1 Subcutaneous omalizumab (Xolair) within 5 months of Visit 1 Intranasal antihistamines (e. g. Astelin) within 2 weeks prior to Visit 1 Use of other medications that may affect allergic rhinitis or its symptoms Chronic use of concomitant medications, such as tricyclic antidepressants, that would affect assessment of the effectiveness of the study drug Chronic use of long-acting beta-agonists (e. g., salmeterol) Chronic use of other intranasally administered medications (e. g., calcitonin-salmon) Nasal irrigation solutions Use of immunosuppressive medications 8 weeks prior to screening and during the study Use of any medications that significantly inhibit the cytochrome P450 subfamily enzyme CYP3A4, including ritonavir and ketoconazole Immunotherapy Subjects may be enrolled into the study if the immunotherapy was not initiated within 30 days of Visit 1, if the dose has remained fixed over the 30 days prior to Visit 1, and the dose will remain fixed for the duration of the study.

Allergy/Intolerance Known hypersensitivity to corticosteroids or any excipients in the product Clinical trial/experimental medication experience Has recent exposure to an investigational study drug within 30 days of Visit 1 Participation in a previous or current GSK FFNS study Positive or inconclusive pregnancy test or female who is breastfeeding Has a positive or inconclusive pregnancy test at Visit 1 or Visit 2 Affiliation with investigational site Subject is a participating investigator, sub-investigator, study co-ordinator, or employee of a participating investigator, or is an immediate family member of the aforementioned.

Current tobacco use Subject currently uses smoking products including cigarettes, cigars, and pipe or chewing tobacco.

Subject must be able to read, comprehend, and record information in English.

GSK Clinical Trials Call Center, Birmingham, Alabama 35209, United States

GSK Clinical Trials Call Center, Phoenix, Arizona 85050, United States

GSK Clinical Trials Call Center, Long Beach, California 90806, United States

GSK Clinical Trials Call Center, San Diego, California 92123, United States

GSK Clinical Trials Call Center, San Diego, California 92120, United States

GSK Clinical Trials Call Center, San Francisco, California 94104, United States

GSK Clinical Trials Call Center, San Jose, California 95117, United States

GSK Clinical Trials Call Center, Vista, California 92083, United States

GSK Clinical Trials Call Center, Los Angeles, California 90025, United States

GSK Clinical Trials Call Center, Tampa, Florida 33613, United States

GSK Clinical Trials Call Center, Tallahassee, Florida 32308, United States

GSK Clinical Trials Call Center, Lilburn, Georgia 30047, United States

GSK Clinical Trials Call Center, Bangor, Maine 04401, United States

GSK Clinical Trials Call Center, Bethesda, Maryland 20814, United States

GSK Clinical Trials Call Center, Ocean, New Jersey 07712, United States

GSK Clinical Trials Call Center, Ithaca, New York 14850, United States

GSK Clinical Trials Call Center, Rockville Center, New York 11570, United States

GSK Clinical Trials Call Center, Durham, North Carolina 27704, United States

GSK Clinical Trials Call Center, Collegeville, Pennsylvania 19426, United States

GSK Clinical Trials Call Center, Philadelphia, Pennsylvania 19107, United States

GSK Clinical Trials Call Center, Philadelphia, Pennsylvania 19115, United States

GSK Clinical Trials Call Center, Charleston, South Carolina 29407, United States

GSK Clinical Trials Call Center, New Braunfels, Texas 78130, United States

GSK Clinical Trials Call Center, Austin, Texas 78750, United States

GSK Clinical Trials Call Center, Dallas, Texas 75246, United States

GSK Clinical Trials Call Center, Dallas, Texas 75231, United States

GSK Clinical Trials Call Center, El Paso, Texas 79925, United States

GSK Clinical Trials Call Center, San Antonio, Texas 78229, United States

GSK Clinical Trials Call Center, Austin, Texas 78731, United States

GSK Clinical Trials Call Center, Dallas, Texas 75230, United States

GSK Clinical Trials Call Center, San Antonio, Texas 78229, United States

Starting date: August 2007
Ending date: November 2007
Last updated: March 3, 2008